Last reviewed · How we verify
NCT03074110
Isocapnic Hyperventilation - an Alternative Method
NA trial testing Isocapnic hyperventilation in Oropharyngeal Neoplasms in 31 participants. Completed in 15 August 2017.
15 August 2017
Quick facts
| Lead sponsor | Sahlgrenska University Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | other |
| Enrollment | 31 |
| Start date | 11 November 2016 |
| Primary completion | 15 August 2017 |
| Estimated completion | 15 August 2017 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Isocapnic hyperventilation
Conditions studied
- Oropharyngeal Neoplasms — all drugs for Oropharyngeal Neoplasms →
Sponsor
Sahlgrenska University Hospital
Who can join
18 and older, any sex, with Oropharyngeal Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Isocapnic hyperventilation (IHV) is a method that shortens time to extubation after inhalation anaesthesia by increasing airway carbon dioxide (CO2) during hyperventilation (HV). In two experimental studies (mechanical lung model and porcine model) and in a pilot study on patients undergoing sevoflurane anaesthesia for major ear-nose-throat (ENT) surgery, the investigators evaluated the feasibility of an alternative technique of IHV. By performing a prospective, randomised controlled study, the investigators want to further test this alternative method for IHV.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03074110
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Oropharyngeal Neoplasms
Currently open trials in the same condition.
- NCT06642324 — Human Papillomavirus Association and Genomic Exploration in Head-Neck Squamous Cell Carcinomas · recruiting
- NCT06167291 — Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nod · Phase 2 · recruiting
Other Sahlgrenska University Hospital trials
Trials by the same sponsor.
- NCT07491094 — Repeated Examinations for Typing Pulmonary Embolism · recruiting
- NCT07524608 — Implementing an Evidence-based, Standardized Care Bundle Targeting Register Nurses and Anaesthesiologists, to Enhance Pa · not yet recruiting
- NCT07498959 — Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer · NA · recruiting
- NCT06896578 — Latitude - Lateral Lymph Node Attitude Study · NA · not yet recruiting
- NCT07035600 — Walking and Sitting Difficulties After Rectal Cancer Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03074110 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sahlgrenska University Hospital
- Last refreshed: 2 January 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03074110.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing